MARKET

LMDX

LMDX

Lumiradx Limited
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.806
-0.114
-3.90%
Opening 10:21 06/29 EDT
OPEN
2.850
PREV CLOSE
2.920
HIGH
2.867
LOW
2.800
VOLUME
7.49K
TURNOVER
18.41K
52 WEEK HIGH
11.09
52 WEEK LOW
2.670
MARKET CAP
703.87M
P/E (TTM)
-4.5393
1D
5D
1M
3M
1Y
5Y
--Ladenburg Thalmann Adjusts LumiraDx Price Target to $12 From $14, Maintains Buy Rating
MT Newswires · 06/14 11:50
BRIEF-LumiraDx Achieves CE Mark For Covid-19 Antigen Test On Amira, Its New Low-Cost Testing System
reuters.com · 06/09 13:50
LumiraDx gets EU's CE mark for its low-cost COVID-19 test, the Amira System
LumiraDx (NASDAQ:LMDX) on Thursday said it had got the European Commission's CE Mark for its Amira System, a low-cost COVID-19 test. The CE marking signifies that products sold in the European Economic Area
Seekingalpha · 06/09 13:27
LumiraDx Achieves CE Mark For COVID-19 Antigen Test On Co's Testing System 'Amira'
LumiraDx Limited (NASDAQ:LMDX), a next-generation point of care diagnostics company, today announced that it has achieved CE Mark for the Amira System, its new testing system that provides low-cost, highly sensitive
Benzinga · 06/09 12:35
LumiraDx Achieves CE Mark for COVID-19 Antigen Test on Amira, its New Low-Cost Testing System
LumiraDx Limited (Nasdaq: LMDX), a next-generation point of care diagnostics company, today announced that it has achieved CE Mark for the Amira System, its new testing system that provides low-cost, highly sensitive COVID-19 testing. The Amira Analyzer re...
PR Newswire · 06/09 12:33
Why LumiraDx Shares Are Rising Today
LumiraDx Ltd (NASDAQ: LMDX) shares are trading higher by 10.31% at $4.28 after the company announced it achieved CE Mark for two new Fast Lab Solutions molecular tests, including Dual-Target SARS-CoV-2 STAR Complete and SARS-CoV-2 & Flu A/B RNA STAR Comple...
Benzinga · 06/08 14:30
DBV, Rubius top healthcare gainers; Rigel, Cosmos lead losers' pack
Gainers: DBV Technologies (DBVT) +21%. Rubius Therapeutics (RUBY) +20%. Annovis Bio (ANVS) +17%. LumiraDx (LMDX) +16%. CTI BioPharma (CTIC) +15%. Losers: Rigel Pharmaceuticals (RIGL) -48%. Cosmos (COSM) -13%. Accelerate Diagnostics (AXDX) -9%. Omeros (OMER...
Seekingalpha · 06/08 14:02
LumiraDx stock rises as COVID/influenza tests get CE mark in Europe
London-based LumiraDx (NASDAQ:LMDX) said its Dual-Target SARS-CoV-2 STAR Complete and SARS-CoV-2 & Flu A/B RNA STAR Complete tests received CE marking in the EU. The LumiraDx SARS-CoV-2 & Flu A/B
Seekingalpha · 06/08 13:04
More
No Data
Learn about the latest financial forecast of LMDX. Analyze the recent business situations of Lumiradx Limited through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

50.00%Strong Buy
50.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average LMDX stock price target is 8.00 with a high estimate of 12.00 and a low estimate of 6.00.
High12.00
Average8.00
Low6.00
Current 2.825
EPS
Actual
Estimate
-0.090.070.240.41
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 24
Institutional Holdings: 15.09M
% Owned: 7.28%
Shares Outstanding: 250.83M
TypeInstitutionsShares
Increased
6
1.19M
New
3
47.59K
Decreased
6
116.74K
Sold Out
4
189.97K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
No Data
No Data
No Data
About LMDX
LumiraDx Limited is a diagnostic company. The Company is focused on transforming community-based healthcare by providing critical diagnostic information to healthcare providers at the point of need. The Company has developed and launched LumiraDx Platform, a platform which is an integrated system comprised of a small, point of care (POC) instrument, microfluidic test strips, and secure digital connectivity. The Company has developed five diagnostic tests which includes SARS-CoV-2 antigen, SARS-CoV-2 antigen pool, SARS-CoV-2 antibody, International Normalized Ratio (INR) test, and D-Dimer test. It has also developed two rapid COVID-19 reagent testing kits for use on open molecular systems, LumiraDx SARS-CoV-2 RNA STAR and SARS-CoV-2 RNA STAR. Its platform has a pipeline of approximately more than 30 tests in various stages of development for the community-based healthcare settings.

Webull offers kinds of LumiraDx Ltd stock information, including NASDAQ:LMDX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LMDX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading LMDX stock methods without spending real money on the virtual paper trading platform.